【Product Name】 silybin meglumine tablets
【Approval number】 Zhunzi H43021882
【Properties】 This product is sugar-coated tablets drugs, removal of coating was yellow.
【Indications】 for acute, chronic, early cirrhosis, toxic liver adjuvant therapy.
【Drug Contraindications】 Hypersensitivity to the chemicals.
【Pharmacological action】 1. Pharmacology: Animal experiments have shown: the onset of elevated liver microsomal enzyme activity, accelerated liver detoxification capacity; also reduce carbon tetrachloride-induced rat serum glutamic - C aminotransferase increased role ; also stable carbon tetrachloride, phalloidin alkali sulfide, acetamide, Crotalaria alkali liver toxic liver damage caused by various types of cell membranes, and to achieve significant liver protection. 2 toxicology: ① mouse acute oral toxicity test LD50 values could not be detected. ② Subacute toxicity test dogs: After oral administration, the heart, lung, liver, kidney, pancreas, spleen, intestine, adrenal gland and other tissues showed no significant changes.
【Drug Interactions】 No Information
【Adverse】 reactions have occasionally dizziness, abdominal discomfort and other reactions.
【Specification】 50mg
【Drug Ingredients】 silybin meglumine
【Pregnant women drug】 No Information
【Pediatric Use】 No Information
【Drugs in elderly patients】No Information
【Dosage】 oral. 3 times a day, a 2 to 4, or as directed.
【Storage】 dark, sealed, in a dry place.
【Precautions】 Hypersensitivity to the chemicals
- This manual is for reference only